Story perspectives

Eli Lilly’s Retatrutide Delivers 18.8% Weight Loss in Trial

By Drooid · Sep 30, 2026, 2:11 AM UTC · How we work

Summary

Story summary

Eli Lilly announced retatrutide caused up to 60-pound weight loss in type-2 diabetes patients.
In the phase-III TRIUMPH-2 trial, 1,152 adults across eight countries received 12 mg retatrutide.
Participants lost an average 18.8% body weight after 80 weeks, with 31% losing at least 25%.
HbA1c fell up to 1.5 points, with 72% achieving <=6.5% versus 29% on placebo.
Diarrhea occurred in 27-34% and nausea in 14-28% of retatrutide recipients.

1 of 1

Story summary

Eli Lilly announced retatrutide caused up to 60-pound weight loss in type-2 diabetes patients.
In the phase-III TRIUMPH-2 trial, 1,152 adults across eight countries received 12 mg retatrutide.
Participants lost an average 18.8% body weight after 80 weeks, with 31% losing at least 25%.
HbA1c fell up to 1.5 points, with 72% achieving <=6.5% versus 29% on placebo.
Diarrhea occurred in 27-34% and nausea in 14-28% of retatrutide recipients.